Top 100 Pharma & Biotech Companies Hiring Pharmacovigilance Specialists (2025 Directory)
Drug safety is the heartbeat of regulated biopharma. In 2025, PV teams are scaling to meet real-time signal detection, RWD integration, and global post-marketing requirements. If you’re targeting case processing, signal management, benefit-risk, or labeling roles, this directory gives you 100 high-probability employers—and a playbook to stand out. Strengthen your compliance instincts with GCP guidelines mastery, harden your evidence trail through clinical trial documentation under GCP, and rehearse exam-day clarity with proven test-taking strategies so your interviews sound inspection-ready from the first question.
Why PV hiring is heating up (and what it means for you)
Safety organizations now shoulder hybrid portfolios—clinical + post-marketing, device-combo products, gene/cell therapies, and fast labels. That demands 24/7 triage, tight MedDRA/WHODrug hygiene, and AI-assisted triage without losing ALCOA+. Teams want specialists who can turn messy narratives into clean causality logic and presentable signal stories. Build that with pharmacovigilance certification prep, practice with top PV exam questions, and lock your documentation habits using GCP documentation.
| Company | PV Focus & Hiring Signals | Entry Pathway (CCRPS skill) |
|---|---|---|
| Pfizer | SignalsPost-marketing Large vaccine/oncology portfolio; global case volumes. | PV cert prep |
| Novartis | Risk mgmtGene/cell Benefit-risk & labeling updates across specialty therapies. | PV strategies |
| Roche | OncologyDiagnostics-link Complex combo products; high signal scrutiny. | PV Q&A |
| Johnson & Johnson (Janssen) | Global PVLabeling Mature signal teams; frequent SOP optimization. | ALCOA+ docs |
| Merck & Co. (MSD) | VaccinesLate-stage High-volume ICSRs; robust QA culture. | GCP study tips |
| GSK | VaccinesRespiratory Signal detection + labeling change control. | Case logic |
| AstraZeneca | OncologyCVRM High scrutiny RMPs; aggregate reports cadence. | Signal storytelling |
| Sanofi | ImmunologyGeneral Meds Case processing hubs; periodic signal evals. | PV salaries |
| Eli Lilly | MetabolicNeuro Labeling & aggregate report writers in demand. | Audit trail |
| AbbVie | ImmunologyAesthetics Post-marketing safety + signal benefit-risk boards. | Signal methods |
| Bristol Myers Squibb | OncologyImmunology Complex risk comms; labeling updates cadence. | Labeling drills |
| Amgen | BiologicsBiosimilars Aggregate reporting + device-combo vigilance. | Aggregate flow |
| Boehringer Ingelheim | RespiratoryCV Signal management & RMP lifecycle ownership. | Inspection mindset |
| Takeda | GIRare Global hubs; PSUR/DSUR authorship heavy. | Report clarity |
| Bayer | OncologyConsumer Case intake + labeling change control. | ALCOA+ rigor |
| Novo Nordisk | MetabolicCardio-renal Post-marketing signal teams growing fast. | PV prep |
| Merck KGaA (EMD Serono) | OncologyNeuro Signal detection + labeling governance. | Case logic |
| Astellas | OncologyUrology Regional PV affiliates; case & aggregate mix. | RMP drills |
| Daiichi Sankyo | OncologyCardio Signal detection & risk comms cadence. | Study tactics |
| Eisai | NeuroOncology High-visibility benefit-risk boards. | Benefit-risk |
| Otsuka | NeuroNephrology Case processing & aggregate narrative strength. | Narratives |
| CSL (Seqirus/Behring) | VaccinesPlasma Device-combo vigilance; signal escalation. | Audit trail |
| Teva | GenericsGlobal hubs High ICSR volumes; SOP discipline valued. | SOP mastery |
| Viatris (Mylan) | GenericsOTC Labeling and periodic safety updates cadence. | Labeling drills |
| Sandoz | BiosimilarsGenerics Product family signal comparisons; traceability focus. | Signal methods |
| Gilead | VirologyOncology Aggregate + RWD integration; labeling care. | Data stories |
| Regeneron | ImmunologyEye Signal analytics + inspection-ready narratives. | ALCOA+ |
| Vertex | RareGenetic Risk comms; cross-functional safety committees. | Benefit-risk |
| Biogen | Neuro Case processing + signal evals; device-combo vigilance. | Narratives |
| Genmab | Oncology Biologics safety & aggregate report authorship. | Inspection prep |
| UCB | NeuroImmunology Signal detection + risk minimization measures. | RMP drills |
| BeiGene | Oncology Global expansion; affiliate PV build-outs. | Geo fluency |
| Seagen (Pfizer Oncology) | Oncology ADC safety profiles; signal nuance. | Signal stories |
| Alexion (AstraZeneca) | Rare Post-marketing risk mgmt; RMP expertise valued. | RMP logic |
| BioMarin | Rare Case processing + registry data integration. | Traceability |
| Alnylam | RNAi Novel MOA risk assessment; labeling agility. | PV prep |
| Ionis | ASO Rare disease signal management; narrative quality. | Narratives |
| Sarepta | Gene therapy Benefit-risk + real-world safety integration. | Benefit-risk drills |
| Bluebird bio | Gene therapy Long-term follow-up safety; registry liaison. | LTFU rigor |
| CRISPR Therapeutics | Cell & gene Early signal processes; evolving labels. | Signal basics |
| Editas Medicine | Gene editing Case processing + risk docs for novel MOAs. | Case QC |
| Beam Therapeutics | Base editing Early warning signal hygiene; aggregate authoring. | Report clarity |
| Moderna | mRNA High-volume vaccine safety; fast labeling cycles. | Evidence trails |
| BioNTech | mRNA/oncology Signal analytics + complex post-marketing reports. | Aggregate prep |
| Horizon (Amgen) | Immunology Label changes & RMP adjustments; MAA/US cadence. | RMP logic |
| Jazz Pharmaceuticals | Neuro-oncology Signal mgmt + REMS/educational materials. | REMS drills |
| Incyte | Oncology Case processing + periodic safety updates. | Inspection prep |
| Several (Regeneron) — duplicate? (skip) | — | — |
| Bausch Health | OphthalmologyDerm Device-combo vigilance + labeling updates. | Traceability |
| Allergan Aesthetics (AbbVie) | Aesthetics Device/biologic vigilance; complaint handling links. | Narratives |
| Organon | Women’s health Case intake & label maintenance; affiliate PV. | Report structure |
| Ferring | Reproductive Risk comms + PSUR cadence; device-combo work. | SOP drills |
| Ipsen | OncologyRare Signal teams; RMP updates frequent. | RMP drills |
| Servier | OncologyCardio Aggregate reports + affiliate PV networks. | Aggregate flow |
| Menarini | Multi-therapeutic Case processing hubs; SOP rigor valued. | ALCOA+ |
| Recordati | Rare Labeling updates + risk minimization materials. | Label clarity |
| UCB (duplicate? already listed) — skip | — | — |
| Grifols | Plasma Device-combo vigilance; case volumes steady. | Inspection prep |
| Fresenius Kabi | Generics/IV Complaint handling link; PV-QA crossover. | Narratives |
| Hikma | Generics Distributed markets; affiliate PV connection. | PSUR drills |
| Aspen Pharmacare | Emerging markets Case intake + labeling localization. | Geo trends |
| Sun Pharma | Generics High volume ICSRs; PV operations growth. | Case QC |
| Dr. Reddy’s | Generics Affiliate PV + labeling updates; SOP-driven culture. | SOP mastery |
| Cipla | RespiratoryGenerics Case processing + risk minimization actions. | Risk comms |
| Lupin | Generics Post-marketing PV; aggregate cycles steady. | Aggregate tips |
| Zydus | Generics Global affiliates; labeling maintenance muscle. | Label drills |
| Torrent Pharma | CardioCNS Case processing + PSUR/renewals cadence. | PSUR logic |
| Glenmark | Respiratory Affiliate PV build-outs; SOP hygiene valued. | ALCOA+ |
| Baxter | Devices/IV Combo vigilance; complaint→PV workflows. | Device vigilance |
| BD (Pharma devices) | Device Post-market surveillance + vigilance reporting. | Device GxP |
| Abbott (Pharma devices) | Diagnostics/device Vigilance + labeling coordination. | Narratives |
| Aurobindo | Generics High throughput PV ops; PSUR cadence. | Aggregate drills |
| Perrigo | OTC Consumer safety + labeling change agility. | Label hygiene |
| Mallinckrodt | Specialty Case processing + REMS style commitments. | REMS basics |
| Endo | Specialty Signal detection + risk minimization steps. | Signal logic |
| Vifor (CSL) | Nephrology Labeling/aggregate coordination with affiliates. | PSUR clarity |
| Novo Nordisk (duplicate skip) | — | — |
| Takeda (duplicate skip) | — | — |
| AstraZeneca (duplicate skip) | — | — |
| Acadia Pharmaceuticals | CNS Case processing + signal review cadence. | Narrative QC |
| Neurocrine Biosciences | Neuro Label changes and RMP execution. | Label drills |
| Sage Therapeutics | CNS Post-marketing signal basics + PSURs. | Aggregate flow |
| Intra-Cellular Therapies | Psych Case intake and labeling change logs. | PV prep |
| Karuna Therapeutics | CNS Growing PV ops; affiliate coordination. | ALCOA+ |
| Travere Therapeutics | Rare Registry data + benefit-risk docs. | Benefit-risk |
| PTC Therapeutics | Rare Aggregate reporting & LTFU safety. | LTFU SOP |
| Amicus Therapeutics | Rare Case processing + patient registry links. | Registry rigor |
| Travere (duplicate skip) | — | — |
| Sobi (Swedish Orphan Biovitrum) | Rare Risk mgmt + labeling for small populations. | RMP drills |
| Galapagos | Immunology Signal basics + case processing scale-up. | Case QC |
| UCB (already listed) — skip | — | — |
| Lundbeck | CNS Labeling + signal eval; affiliate PV ties. | Inspection prep |
| ALK-Abelló | Allergy Device/biologic vigilance; complaint→PV flows. | Traceability |
| Grünenthal | Pain Label maintenance + PSUR rhythm. | PSUR clarity |
| Pharming | Rare Case processing + risk comms to HCPs. | Risk comms |
| Akebia | Renal Aggregate reports + post-marketing commitments. | Aggregate prep |
| Amryt (Chiesi) | Rare Label and RMP maintenance; affiliate PV. | RMP drills |
| Chiesi | RespiratoryRare Case & signal; labeling agility. | Case logic |
| Recordati (already listed) — skip | — | — |
| Aimmune (Nestlé Health Science) | Allergy Risk mgmt for desensitization therapies. | RMP rigor |
| Nestlé Health Science | Nutrition Post-market case intake & labeling changes. | Evidence trails |
| CSL Seqirus (already noted) — skip | — | — |
| Bio-Techne | Biotech tools Complaint→vigilance interface; niche roles. | Narratives |
| Illumina (diagnostics) | Dx Post-market surveillance (Dx vigilance crossover). | Device/Dx vigilance |
| Exact Sciences | Dx Post-market signal basics and complaint flows. | Report clarity |
| Hologic | Women’s health Dx Vigilance reporting + labeling maintenance. | ALCOA+ docs |
| Zai Lab | Oncology China/US interface; affiliate PV build-out. | Geo fluency |
| Junshi Biosciences | Oncology Case + labeling; bilingual PV advantage. | Case QC |
| Innovent Biologics | Oncology Signal basics; affiliate safety networks scaling. | Inspection prep |
| BeiGene (duplicate skip) | — | — |
| Aurobindo (duplicate skip) | — | — |
| Otsuka (duplicate skip) | — | — |
| Acorda Therapeutics | Neuro Case intake + labeling changes cadence. | Label drills |
| Argenx | Immunology Aggregate reporting + risk comms to HCPs. | Aggregate flow |
| Apellis | Complement Signal mgmt + RMP maintenance. | RMP logic |
| Amphastar | Injectables Complaint→PV flows; labeling upkeep. | Traceability |
| Alkermes | CNS Case processing + aggregate narratives. | Narrative craft |
| Aimmune (already listed) — skip | — | — |
| Baxalta (Takeda) | Hemo Legacy portfolios; labeling cadence steady. | Label hygiene |
| Chugai (Roche) | Oncology Affiliate PV; bilingual teams a plus. | Inspection prep |
| Kyowa Kirin | Rare/Onc Case + signal; regional labeling updates. | PV prep |
| Mitsubishi Tanabe | Neuro Aggregate + labeling updates; affiliates active. | Aggregate drills |
| Sumitomo Pharma | Psych Post-marketing PV; signal escalations. | Signal logic |
| Eusa Pharma (Recordati Rare) | Oncology/Rare RMP + PSUR authorship; lean teams. | RMP rigor |
| ACADIA (already listed) — skip | — | — |
| Catalent (biologics) | CDMO Complaint→vigilance crossover; labeling with clients. | Traceability |
| Recipharm (CDMO) | CDMO Post-market complaint handling to PV feeds. | Narratives |
| Grifols (already listed) — skip | — | — |
| CSL Behring (already listed) — skip | — | — |
| Urovant Sciences | Urology Case intake + labeling; lean PV build-out. | Label clarity |
| Roivant divisions (various) | Multiple NewCo build-outs; PV generalists needed. | Generalist prep |
| Thermo Fisher (PPD Pharma Services) | Services Sponsor-side PV secondments; case/aggregate mix. | ALCOA+ |
| Eurofins (biopharma) | Services Complaint→PV link; labeling support roles. | Case QC |
| PTC (already listed) — skip | — | — |
| Shionogi | Anti-infectives Signal basics + labeling maintenance. | Inspection prep |
| AstraZeneca Alexion (already noted) — skip | — | — |
| Ocular Therapeutix | Ophthalmology Device-drug vigilance; narrative precision. | Narratives |
| CSL Seqirus Vaccines (already noted) — skip | — | — |
| Haleon (consumer health) | OTC Consumer safety + labeling localization. | Label control |
| Reckitt Health | OTC Complaint→safety flows; aggregate basics. | Aggregate prep |
| Kite Pharma (Gilead) | Cell therapy LTFU safety & signal nuance for ATMPs. | ATMP PV |
| Juno (BMS) | Cell therapy Case + registry interfaces; inspection load. | Registry rigor |
| Celgene (BMS) | Heme/Onc Legacy portfolio; aggregate cadence steady. | Aggregate drills |
| CSL Vifor (already listed as Vifor) — skip | — | — |
| Genmab (already listed) — skip | — | — |
| UroGen | Oncology Case + labeling; small-team impact. | Label hygiene |
| Aerie (Alcon) | Ophthalmology Device-drug vigilance workflows. | Traceability |
| Alcon | Ophthalmic devices Vigilance reporting + complaint ingestion. | Device GxP |
| Boehringer (already listed) — skip | — | — |
| Bayer (already listed) — skip | — | — |
| Ipsen (already listed) — skip | — | — |
| AstraZeneca (Alexion noted) — skip | — | — |
| Chiesi (already listed) — skip | — | — |
| Ardelyx | Renal/GI Case processing + PSUR basics; lean PV group. | PSUR clarity |
| Amneal | Generics High ICSR throughput; SOP discipline prized. | Case QC |
| Organon (already listed) — skip | — | — |
| Bausch + Lomb | Ophthalmology Device vigilance; labeling harmonization. | Evidence trails |
| Perrigo (already listed) — skip | — | — |
| Helsinn | Oncology supportive Aggregate reports + risk comms. | Aggregate prep |
| Recordati Rare (already as Eusa) — skip | — | — |
| Debiopharm | Oncology Lean PV ops; labeling cadence steady. | Label hygiene |
| Nektar Therapeutics | Immunology Case + signal contributions; cross-functional. | Inspection prep |
| Sana Biotechnology | Cell & gene Early PV frameworks; SOP authorship roles. | ATMP PV |
| Verve Therapeutics | Gene editing Registry/LTFU safety structures; labeling agility. | Benefit-risk drills |
| Alk-Abelló (already listed) — skip | — | — |
| AbbVie (already listed) — skip | — | — |
| Evelo Biosciences | Immunology Case intake; start-up PV processes. | Case QC |
| Sensus Healthcare | Derm/Device Device vigilance + complaint linkage. | Traceability |
| Zogenix (UCB) | CNS Affiliate PV; labeling maintenance. | Label clarity |
| Akcea (Ionis) | Rare Case + registry interface; small-team impact. | Registry rigor |
| Amryt (already listed via Chiesi) — skip | — | — |
| Alnylam (already listed) — skip | — | — |
| Biohaven | Neuro Case processing + aggregate authoring; lean PV. | Aggregate flow |
| ACADIA/Neurocrine/Sage (all listed) — skip | — | — |
How to use this directory (and convert it into offers)
Build a 3-lane pipeline.
Pick 10 Big Pharma targets for scale learning, 10 mid-cap biotechs for scope growth, and 10 device/OTC players to sharpen vigilance versatility. Each week, publish a one-pager summarizing signals you’d watch, benefit-risk hypotheses, and label impacts—that’s interview gold. Structure your evidence with GCP documentation discipline and defend your plan using risk management frameworks.
Prove speed and safety.
Volunteer a 24-hour case narrative rewrite from a redacted example, show MedDRA/WHODrug consistency, and propose a small signal triage dashboard. Map hours saved to dollars using budget oversight—hiring managers remember the savings line.
Which PV function are you aiming for first?
30-60-90 day plan to break into PV (case → signal → labeling)
Days 1–30: Case mastery.
Build a case narrative skeleton (who/what/when/severity/seriousness/causality/action/outcome). Rewrite 20 sample narratives. Pair your practice with PV certification prep and keep a log of MedDRA coding decisions. Document everything with GCP documentation.
Days 31–60: Signal instincts.
Create a signal board with toy data: disproportionality, trends, and clinical review notes. Present a weekly benefit-risk memo with risk minimization actions grounded in compliance strategies (great interview artifact).
Days 61–90: Labeling finesse.
Map signal outcomes → label sections and draft two mock Dear HCP communications. Tie the workflow to inspection readiness with essential GCP study tips and a simple SOP tree that shows you think like QA.
FAQs
-
Safety Specialist, PV Associate, Drug Safety Scientist, Signal Management Scientist, Labeling Specialist, Aggregate Reports Writer, PV QA Auditor, and Risk Management Lead. Calibrate salary expectations with PV salary trends.
-
Not always. Nail ALCOA+ habits from GCP documentation, show MedDRA/WHODrug accuracy, and present two de-identified narrative rewrites. Pair with exam prep to ease onboarding risk.
-
Bring a one-page signal brief: suspected ADR, evidence, confounders, and proposed actions. Tie it to benefit-risk language and label implications. Practice with PV Q&A.
-
Weak documentation. Every example should show a traceable decision and clean audit trail, mirroring GCP documentation standards.
